The global antiviral drugs market is expected to reach US$70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024.

The factors such as, increasing prevalence of HIV infections, upswing in international tourism, growth in geriatric population, increasing pharmaceutical R&D spending, rapid urbanization, upsurge in healthcare spending and growing awareness about various viral diseases are expected to drive the growth of the market.

Fill This Form and get the Sample Copy of This Report: https://www.sdki.jp/sample-request-62248


"The Final Report will cover the impact analysis of COVID-19 on this industry (Global Antiviral Drugs Market)."

However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations. A few notable trends may include accelerating growth rate of infectious diseases, increasing focus on telehealth, growth in pharmaceutical Merger & acquisitions and emergence of new infectious diseases.

The fastest growing regional market was North America owing to the presence of key players in the region, availability of sophisticated healthcare infrastructure and increasing awareness of viral diseases among people.

Fill This Form and get the Sample Copy of This Report: https://www.sdki.jp/sample-request-62248


"The Final Report will cover the impact analysis of COVID-19 on this industry (Global Antiviral Drugs Market)."

Whereas, Europe and Asia Pacific also contributed to significant shares in the global market due to the factors such as increase in patient pool of various infectious diseases and rise in the acceptance of generic drugs.

Scope of the report:
The report provides a comprehensive analysis of the global antiviral drugs market.
The major regional markets (North America, Europe, Asia-Pacific Middle East & Africa) have been analyzed.
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Merck & Co., AbbVie Inc., Bristol-Myer Squibb, Gilead Sciences and Cipla) are also presented in detail.

Key Target Audience:
Antiviral Drugs Manufacturers
Pharmaceuticals and Biopharmaceutical Firms
End Users (Hospitals, Clinics, Pharmacies, Drugs Stores, etc.)
Investment Banks
Healthcare and Medical Consultants
Government Bodies & Regulating Authorities

+ Table Of Content +
1. Overview
1.1 Introduction
1.2 Viral Life Cycle
1.3 Antiviral Agents
1.4 Development of Antiviral Drugs
1.5 Some Major Antiviral Compounds
2. Impact of COVID-19
2.1 Rise in COVID-19 Death Toll
2.2 Growth in Government Spending on Healthcare
2.3 COVID-19 Antiviral Candidate Drugs in Trial
2.4 Regional Impact
3. Remdesivir and COVID-19
3.1 Remdesivir
3.2 Major Clinical Studies of Remdesivir
3.3 Emergency Use of Remdesivir